@article{22db6bc27baf4ef786d867de0cf3bb99,
title = "Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011–2017",
abstract = "Opioid therapy is a first-line approach for moderate-to-severe pain associated with cancer with bone metastasis (CBM). The decade-long decline in opioid prescribing in the U.S. would not be expected to affect patients with CBM. We investigated trends in opioids dispensed to patients with CBM using data from a large commercial claims database. From 2011 quarter 2 to 2017 quarter 4, the percentage of patients with CBM prescribed at least 1 day of opioids in a quarter declined from 28.1% to 24.5% (p <.001) for privately insured patients aged 18–64 years and from 39.1% to 30.5% (p <.001) for Medicare Advantage (MA) patients aged 65 years or older. Among patients with at least 1 day of opioids in a quarter, the average morphine milligram equivalents dispensed declined by 37% and 11% (p <.001 for both) for privately insured and MA patients, respectively. Our findings raise concerns about potential unintended consequences related to population-level reduction in opioid prescribing.",
author = "Hao Zhang and Judith Paice and Russell Portenoy and Eduardo Bruera and Reid, {M. Carrington} and Yuhua Bao",
note = "Funding Information: We thank Phyllis Johnson and Katherine Wen for their excellent assistance with Health Care Cost Institute (HCCI) data management. This research is supported by a pilot award from the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, a Center of Excellence funded by the National Institute on Drug Abuse (P30DA040500). The research team's access to the HCCI data was supported by the Health Data for Action program of the Robert Wood Johnson Foundation. We acknowledge the assistance of HCCI and its data contributors, Aetna, Humana, and UnitedHealthcare, in providing the claims data analyzed in this study. This research was funded by a grant from the Arnold Ventures and by the National Institute on Drug Abuse (NIDA) under the grant P30DA040500. Funding Information: We thank Phyllis Johnson and Katherine Wen for their excellent assistance with Health Care Cost Institute (HCCI) data management. This research is supported by a pilot award from the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV, a Center of Excellence funded by the National Institute on Drug Abuse (P30DA040500). The research team's access to the HCCI data was supported by the Health Data for Action program of the Robert Wood Johnson Foundation. We acknowledge the assistance of HCCI and its data contributors, Aetna, Humana, and UnitedHealthcare, in providing the claims data analyzed in this study. This research was funded by a grant from the Arnold Ventures and by the National Institute on Drug Abuse (NIDA) under the grant P30DA040500. Publisher Copyright: {\textcopyright} 2021 AlphaMed Press.",
year = "2021",
month = oct,
doi = "10.1002/onco.13898",
language = "English (US)",
volume = "26",
pages = "e1890--e1892",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",
}
